Evidence map›Paper›PMID 29471120›Full record

ArticleEuropean journal of medicinal chemistry2018

The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to

Cesar Gonzalez, Andersson Sanchez, Jeffrey Collins, Ksenia Lisova, Jason T Lee, R Michael van Dam, M Alejandro Barbieri, Cheppail Ramachandran, Stanislaw F Wnuk

Open access · greenAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. SyntheticRSC medicinal chemistry · 2024
    Review
  2. Synthesis andRSC medicinal chemistry · 2020
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Cesar GonzalezDepartment of Chemistry and Biochemistry, Florida International University, Miami, FL, 33199, United States.
Andersson SanchezDepartment of Chemistry and Biochemistry, Florida International University, Miami, FL, 33199, United States.
Jeffrey CollinsCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, United States.
Ksenia LisovaCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, United States; Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, United States.
Jason T LeeCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, United States.
R Michael van DamCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, United States; Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, United States.
M Alejandro BarbieriDepartment of Biological Sciences, Florida International University, Miami, FL, 33199, United States.
Cheppail RamachandranNicklaus Children's Hospital, Miami, FL, 33155, United States.
Stanislaw F WnukDepartment of Chemistry and Biochemistry, Florida International University, Miami, FL, 33199, United States. Electronic address: wnuk@fiu.edu.
Florida International University · USInstitute for Molecular Medicine · USUniversity of California, Los Angeles · USMiami Children's Hospital · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
MBRS RESEARCH INITIATIVE FOR SCIENTIFIC ENHANCEMENTR25GM061347 · NIGMS · FLORIDA INTERNATIONAL UNIVERSITY · PI LICKLITER, ROBERT E · 2000 to 2016
$14.7M
Research Training in Biomedical PhysicsT32EB002101 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Michael F McNitt-Gray · 2003 to 2026
$5.3M
Automated microfluidic production of high specific activity PET tracers to enable routine CNS imagingR21AG049918 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2015 to 2017
$693k
NCI NIH HHS P30 CA016042NIA NIH HHS R21 AG049918NIBIB NIH HHS T32 EB002101NIGMS NIH HHS R25 GM061347
6 · The paper itself

Abstract

The coupling of gemcitabine with functionalized carboxylic acids using peptide coupling conditions afforded 4-N-alkanoyl analogues with a terminal alkyne or azido moiety. Reaction of 4-N-tosylgemcitabine with azidoalkyl amine provided 4-N-alkyl gemcitabine with a terminal azido group. Click reaction with silane building blocks afforded 4-N-alkanoyl or 4-N-alkyl gemcitabine analogues suitable for fluorination. RP-HPLC analysis indicated better chemical stability of 4-N-alkyl gemcitabine analogues versus 4-N-alkanoyl analogues in acidic aqueous conditions. The 4-N-alkanoyl gemcitabine analogues showed potent cytostatic activity against L1210 cell line, but cytotoxicity of the 4-N-alkylgemcitabine analogues was low. However, 4-N-alkanoyl and 4-N-alkyl analogues had comparable antiproliferative activities in the HEK293 cells. The 4-N-alkyl analogue with a terminal azide group was shown to be localized inside HEK293 cells by fluorescence microscopy after labelling with Fluor 488-alkyne. The [

Indexed as

Fluorine RadioisotopesAnimalsCell Line, TumorDeoxycytidineFluoridesGastrointestinal TractGemcitabineHEK293 CellsHumansKidneyLiverMicePositron-Emission TomographySilicon CompoundsTissue DistributionDeoxycytidineFluoridesFluorine RadioisotopesGemcitabineSilicon Compoundssilicon fluoride

Identifiers

PMID29471120
PMCPMC5841594
OpenAlexW2793709334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.